levofloxacinstarry
starry 时间:2021-01-09 阅读:(
)
RegulatoryStoryGotomarketnewssectionCompanyCathayInternationalHoldingsLdTIDMCTIHeadlineZhejiangStarryPharmaceuticalCo.
,Ltd.
Released07:0016-Nov-2010Number2440W07RNSNumber:2440WCathayInternationalHoldingsLd16November2010CATHAYINTERNATIONALHOLDINGSLIMITEDProposedminorityinvestmentinZhejiangStarryPharmaceuticalCo.
,Ltd.
('Starry')CathayInternationalHoldingsLtd.
(LSE:CTI.
L)('Cathay'orthe'Company'),acompanyinvestingprimarilyinthegrowingpharmaceuticalandhealthcaresectorsinthePeople'sRepublicofChina('PRC'),announcestodaythat:·LansenPharmaceuticalHoldingsLimited(HKE:503.
HK)('Lansen'),theCompany'ssubsidiarylistedonthemainboardoftheHongKongExchange,hasannouncedtodaythatithasagreedthetermsforthepurchaseofa20%equityinterestinStarry('Lansen'sInvestment')fromanindependentthirdpartyforacashconsiderationofapproximatelyUS$24million;and·theCompanyhasagreedthetermsforthepurchaseofa1.
5%equityinterestinStarry(the'Company'sInvestment')fromthesameindependentthirdpartyforacashconsiderationofapproximatelyUS$1.
8million.
DetailsofthetransactionLansen'sInvestmentistobeeffectedpursuanttoanequitytransferagreement(the'LansenAgreement')underwhichLansenInvestments(HongKong)Limited('LSI'),anindirectwhollyownedsubsidiaryofLansen,hasagreedtopurchaseandMr.
LiewYewThoong(the'Vendor'),oneoftheexistingminorityshareholdersofStarry,hasagreedtosell,20%oftheregisteredcapitalofStarryforacashconsiderationofapproximatelyUS$24million(RMB160million).
TheCompany'sInvestmentistobeeffectedpursuanttoaseparateequitytransferagreement(the'CathayAgreement')underwhichFullKeenLimited('FKL')anindirectwholly-ownedsubsidiaryoftheCompany,hasagreedtopurchaseandtheVendorhasagreedtosell,1.
5%oftheregisteredcapitalofStarryforacashconsiderationofapproximatelyUS$1.
8million(RMB12million).
ZhejiangStarryPharmaceuticalCo.
,Ltd.
-LondonStockExchangehttp://www.
londonstockexchange.
com/exchange/news/market-news/mar.
.
.
1of411/16/20103:03PMInformationonStarryStarryisasino-foreignequityjointventureincorporatedunderthelawsofthePRC.
Itisacompanyspecializingintheproductionofbulkpharmaceuticalsandintermediates.
ThetwocorebulkpharmaceuticalproductsofStarryareiohexolforX-CTnon-ioniccontrastagentsandlevofloxacinforantibiotics.
StarryisthelargestiohexolmanufacturerinthePRCandisexperiencedintheproductionmanagementandqualitycontrolofbulkpharmaceuticals.
SetoutbelowisasummaryoftheauditedfinancialresultsofStarryforthetwoyearsended31December2008and31December2009,whichwerepreparedinaccordancewiththePRCgenerallyacceptedaccountingprinciples:Yearended31December20092008EquivalentEquivalentRMB'000US$'000RMB'000US$'000Profitbeforetaxation57,9748,72532,8604,945Profitaftertaxation57,9748,72532,8604,945Grossassets549,49182,698467,79470,403Netassets199,70730,056139,05320,927ConsiderationTheconsiderationforLansen'sInvestmentisRMB160million(approximatelyUS$24million),whichshallbefundedthroughtheexistinginternalresourcesoftheLansengroup.
TheconsiderationfortheCompany'sInvestmentisRMB12million(approximatelyUS$1.
8million).
TheconsiderationwillbesatisfiedoutoftheCompany'sinternalresources.
Theconsiderationwasagreedafterarm'slengthnegotiationsbetweenLansen,theCompanyandtheVendor,takingintoconsideration,amongstotherthings,(i)thenetassetvalueofStarryasat31December2009;(ii)futureprospectsofthebusinessofStarry;(iii)theprospectsofthepharmaceuticalindustryinthePRCasawhole;and(iv)tradingpriceearningsmultiplesofStarry'smarketcomparablesinthePRC.
TheconsiderationpayablefortheCompany'sInvestmentandLansen'sInvestmentshallbesettledwithin10businessdaysofreceiptoftherelevantgovernmentapprovalinthePRCforthetransferoftheequityinterestsundertherespectiveagreement.
Iftherelevantgovernmentapprovalforthetransferoftheequityinterestsisnotreceivedwithin60daysfromthedateoftheapplicationforapproval(orsuchotherdateastheVendorandLSIorFKL,asthecasemaybe,mayagree)theLansenAgreementandtheCathayAgreementshalllapseandbeofnofurtherforceandeffect.
EffectofthetransactionontheCathaygroupandbenefitsofthetransactionThereasonsforandexpectedbenefitsofLansen'sInvestmentincludethefollowingmatters:·OneofLansen'sstrategiesistoexploreopportunities,throughbusinessalliancesoracquisitions,whichwouldexpanditsproductrangeofrheumaticspecialtydrugs,includingtheupstreambulkpharmaceuticalproductionforrheumaticspecialtydrugs.
TheboardofLansenbelievesthatLansen'sInvestmentprovidesLansenwithopportunitiestoparticipateintheupstreamZhejiangStarryPharmaceuticalCo.
,Ltd.
-LondonStockExchangehttp://www.
londonstockexchange.
com/exchange/news/market-news/mar.
.
.
2of411/16/20103:03PMsupplybusinessinthepharmaceuticalindustryvaluechain.
Lansen'sInvestmentisofstrategicsignificancesinceLansen'sInvestmentwillallowittodevelopexperienceintheproductionmanagementandcontrolofbulkpharmaceuticalsforitsdrugsinthefuture.
·Theimpactonbulkpharmaceuticalsappeartobelesssubstantialthantheimpactondownstreampharmaceuticalproductsundertherecent"DrugPriceControlMeasures"discussionpaperpublishedbythePRCgovernment.
Lansen'sInvestmentwillachieveacertaindegreeofdiversificationofproductconcentrationrisk.
·Lansen'sboardbelievesthatLansen'sInvestmentisconsistentwithLansen'sbusinessobjectiveofestablishingandstrengtheningbusinessallianceswithpharmaceuticalcompanies.
LansenwillbenefitfromStarry'sexperienceinareasincludingrawmaterialsproductiontechnology,GMPcertification,costandqualitycontrol,andenvironmentalprotection.
LansenisnotexpectedtodevotesignificanthumanandmanagementresourcestoStarry'soperations.
·Lansen'sboardconsidersthatthetermsandconditionsoftheLansenAgreement,includingtheconsiderationthereof,arefairandreasonableandthattheenteringintooftheLansenAgreementisintheinterestsofLansenanditsshareholdersasawhole.
ForCathay,theCompany'sInvestmentisinlinewiththeintentionstatedintheCompany's2010interimreporttospecializeinthefastgrowingpharmaceutical,healthcareandenvironmentprotectionmarketsandtowidentheinvestmentscopeoftheCathayGrouptoincludepotentialminorityinvestmentpositions.
TheBoardofCathayconsidersthatthetermsandconditionsoftheCathayAgreement,includingtheconsiderationthereof,arefairandreasonableandthattheenteringintooftheCathayAgreementisintheinterestsoftheCompanyanditsshareholdersasawhole.
DetailsofkeyindividualsimportanttothebusinessofStarryMr.
HuJinsheng,56,founderandoneofthemajorshareholdersofStarry,hasbeeninthebusinessforthirtyyearsandpossessesextensiveexperienceinoperationalandfinancialmanagementissues.
Mr.
HuJinshengistheGeneralManagerofStarry.
Mr.
HuJian,thesonofMr.
HuJinsheng,isanothermajorshareholderofStarry.
Mr.
HuJianistheDeputyGeneralManagerofStarry.
EnquiriesCathayInternationalHoldingsLimited+85228289289JinyiLee/EricSiuBrunswick+44(0)2074045959JonColesCertainstatementsinthisannouncementareforward-lookingstatements.
ThesestatementsrelatetotheCathayGroup'sfutureprospects,developmentsandbusinessstrategies.
Forward-lookingstatementsareidentifiedbytheiruseoftermsandphrasessuchas"believe","could","envisage","estimate","intend","may","plan","will"orthenegativeofthose,variationsorcomparableexpressions,includingreferencestoassumptions.
Theforward-lookingstatementsinthisannouncementarebasedoncurrentexpectationsandaresubjecttorisksanduncertaintiesthatcouldcauseactualresultstodiffermateriallyfromthoseexpressedorimpliedbythosestatements.
Giventheserisksanduncertainties,potentialinvestorsshouldnotplaceanyrelianceonforward-lookingZhejiangStarryPharmaceuticalCo.
,Ltd.
-LondonStockExchangehttp://www.
londonstockexchange.
com/exchange/news/market-news/mar.
.
.
3of411/16/20103:03PMstatements.
Theseforward-lookingstatementsspeakonlyasatthedateofthisannouncement.
NeithertheDirectorsnortheCompanyundertakeanyobligationtoupdateforward-lookingstatementsotherthanasrequiredbytheListingRules,DisclosureandTransparencyRules,applicablelegislationorbytherulesofanyothersecuritiesregulatoryauthority,whetherasaresultofnewinformation,futureeventsorotherwise.
ThisinformationisprovidedbyRNSThecompanynewsservicefromtheLondonStockExchangeENDMSCDMMMMVVRGGZGLondonStockExchangeplcisnotresponsibleforanddoesnotcheckcontentonthisWebsite.
Websiteusersareresponsibleforcheckingcontent.
Anynewsitem(includinganyprospectus)whichisaddressedsolelytothepersonsandcountriesspecifiedthereinshouldnotberelieduponotherthanbysuchpersonsand/oroutsidethespecifiedcountries.
Termsandconditions,includingrestrictionsonuseanddistributionapply.
2009LondonStockExchangeplc.
AllrightsreservedRegulatoryZhejiangStarryPharmaceuticalCo.
,Ltd.
-LondonStockExchangehttp://www.
londonstockexchange.
com/exchange/news/market-news/mar.
.
.
4of411/16/20103:03PM
趣米云早期为做技术起家,为3家IDC提供技术服务2年多,目前商家在售的服务有香港vps、香港独立服务器、香港站群服务器等,线路方面都是目前最优质的CN2,直连大陆,延时非常低,适合做站,目前商家正在做七月优惠活动,VPS低至18元,价格算是比较便宜的了。趣米云vps优惠套餐:KVM虚拟架构,香港沙田机房,线路采用三网(电信,联通,移动)回程电信cn2、cn2 gia优质网络,延迟低,速度快。自行封...
虎跃科技怎么样?虎跃科技(虎跃云)是一家成立于2017年的国内专业服务商,专业主营云服务器和独立服务器(物理机)高防机房有着高端华为T级清洗能力,目前产品地区有:山东,江苏,浙江等多地区云服务器和独立服务器,今天虎跃云给大家带来了优惠活动,为了更好的促销,枣庄高防BGP服务器最高配置16核32G仅需550元/月,有需要的小伙伴可以来看看哦!产品可以支持24H无条件退款(活动产品退款请以活动规则为准...
传统农历新年将至,国人主机商DogYun(狗云)发来了虎年春节优惠活动,1月31日-2月6日活动期间使用优惠码新开动态云7折,经典云8折,新开独立服务器可立减100元/月;使用优惠码新开香港独立服务器优惠100元,并次月免费;活动期间单笔充值每满100元赠送10元,还可以参与幸运大转盘每日抽取5折码,流量,余额等奖品;商家限量推出一款年付特价套餐,共100台,每个用户限1台,香港VPS年付199元...
starry为你推荐
电信主机租用请问放个服务器在电信机房一般要什么配置?租金多少?中文域名注册查询中文.com域名是什么,怎么注册ip代理地址使用IP代理会有什么坏处吗?虚拟主机申请域名申请以及虚拟主机云服务器租用租用云服务器,要注意什么?域名备案什么是域名备案?网站空间价格域名空间一般几钱?北京虚拟主机北京服务好的虚拟主机代理商介绍几个?论坛虚拟主机我要做个论坛,是用虚拟主机呢?还是用空间?除论坛外还有好及个单页,还带数据库。美国虚拟主机购买我公司需要购买美国的虚拟主机。但是为什么有的海外主机很便宜!有的却很贵呢。 质量如何区分!有没办法去
独立ip主机 vps推荐 西安电信测速 名片模板psd 国外空间 发包服务器 丹弗 e蜗牛 40g硬盘 193邮箱 架设服务器 新家坡 江苏双线服务器 万网主机管理 1元域名 架设邮件服务器 lick 域名转入 攻击服务器 数据湾 更多